Browse > Article
http://dx.doi.org/10.5385/jksn.2011.18.2.409

Surfactant Replacement Therapy for RDS: a Collaborative Study of 72 Multi-center Trials in Korea (2010) and a Review of Korean Experiences over 20 Years  

Bae, Chong-Woo (Department of Pediatrics, Kyung Hee University School of Medicine)
Hahn, Won-Ho (Department of Pediatrics, Kyung Hee University School of Medicine)
Chang, Ji-Young (Department of Pediatrics, Kyung Hee University School of Medicine)
Kim, Sung-Mi (Department of Pediatrics, Busan St. Mary's Medical Center)
Publication Information
Neonatal Medicine / v.18, no.2, 2011 , pp. 409-411 More about this Journal
Abstract
In Korea, pulmonary surfactant (PS) replacement therapy in respiratory distress syndrome (RDS) was started in 1991 since when Surfacten$^{(R)}$ was imported from Japan. At the present time, Surfacten$^{(R)}$, Newfactan$^{(R)}$, Curosurf$^{(R)}$, and Infasurf$^{(R)}$ are available in Korea. The governmental health insurance covers the expense for multiple dose treatment since 2002 and the early prophylactic treatment (BW: <1,250 g or GP: <30 wks) since 2011. We undertook a multi-institutional collective study to evaluate the outcomes of PS over past 20 years in Korea (Period-I; 1990/91, P-II; 1996, P-III; 2002, and P-IV; 2007, P-V; 2010). There were 60 RDS neonates with PS treatment in P-I (16 hospitals), 1,179 in P-II (64), 1,595 in P-III (62), 1,921 in P-IV (57), and 3,160 in P-V (72). Decreased mortality rate, defined as the percentage of neonates who died within 28 days of birth, was seen between periods, P-V vs P-I, II, III, and IV (mortality rate: 10.1% vs. 40.0%, 30.0%, 18.7%, and 14.3%). We conclude that PS therapy contributed to improve remarkable outcome in RDS neonates over the last 20 years in Korea. However, more efforts should be made to optimize PS therapy for better outcome. Multiple PS doses for relapse and poor response, early prophylactic use, and better supportive care for pre-term infants are mandatory.
Keywords
Respiratory distress syndrome; Newborn; Premature; Complications; Epidemiology mortality pulmonary surfactant; Analysis therapeutic use data collection;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Fujiwara T, Maeta H, Chida S, Morita T, Watabe Y, Abe T. Artificial surfactant therapy in hyaline-membrane disease. Lancet 1980;1:55-9.
2 Intercontinental Medical Statistics Korea. Available at http://www.imskorea.or.kr/ [accessed on 15 Aug. 2011]
3 Namgung R, Lee C, Park KI, Han DG. Exogenous surfactant replacement therapy of hyaline membrane disease: a controlled clinical trial. J Korean Pediatr Soc 1990;33:22-35.
4 Park CO, Lim BY, Yeo BG, Song JH, Sohn EK, Bae CW, et al. Surfactant replacement therapy in neonatal respiratory distress syndrome. J Korean Pediatr Soc 1991;34:1211-22.
5 Bae CW, Kwon YD, Ko SJ, Kim KS, Kim HM, Park WS, et al. Surfactant replacement therapy in neonates with respiratory distress syndrome: a collective evaluation of trials from 16 hospitals. J Korean Pediatr Soc 1993;36:244-65.
6 Bae CW. Surfactant replacement therapy in RDS: a collaborative study of multi-center trials in Korea. J Korean Soc Neonatol 1997;1:124-35.
7 Bae CW, Kim YM. Surfactant therapy for neonatal respiratory distress syndrome: experience in Korea over 15 Years. Korean J Pediatr 2004;47:940-8.
8 Bae CW, Hahn WH. Surfactant therapy for neonatal respiratory distress syndrome: a review of Korean experiences over 17 years. J Korean Med Sci 2009;24:1110-8.   DOI   ScienceOn
9 Chang JY, Lee KS, Hahn WH, Chung SH, Choi YS, Shim KS, et al. Decreasing trends of neonatal and infant mortality rates in Korea: compared with Japan, USA, and OECD nations. J Korean Med Sci. 2011;26:1115-23.   DOI   ScienceOn
10 Halliday HL. Surfactants: past, present and future. J Perinatol 2008; 28 Suppl 1:S47-56.
11 Kim SM, Yoon HS, Kim KS, Bae CW. The importance and the need of early pulmonary surfactant therapy in premature infant with respiratory distress syndrome. J Korean Soc Neonatol 2009;16:101-9.